An Open Label Study of Abiraterone Acetate in Subjects With Metastatic Castration-Resistant Prostate Cancer Who Have Progressed After Taxane-Based Chemotherapy
Phase of Trial: Phase III
Latest Information Update: 01 Feb 2017
At a glance
- Drugs Abiraterone acetate (Primary) ; Prednisone
- Indications Prostate cancer
- Focus Adverse reactions; Registrational
- Sponsors Janssen Research & Development; Janssen-Cilag
- 14 Mar 2016 According to a Janssen Cilag media release, data from the post-hoc analysis of this phase 3 COU-AA-302 trial was presented at the European Association of Urology (EAU).
- 14 Mar 2016 Results of post-hoc analysis published in the Janssen Cilag media release.
- 03 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History